ArticleFrontiers in immunology2025
Variable innate lymphoid cells predominancy in oral lichen planus latently led to diverse clinical outcomes: a proof-of-concept study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Humoral immune activation within tertiary lymphoid structures is correlated with poor outcomes in oral lichen planus and lichenoid lesions.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To search for a new classification scheme for oral lichen planus (OLP) and oral lichenoid lesions (OLL) based on innate lymphoid cells (ILCs) and to evaluate the clinical significance of this classification for diagnosis and treatment. Subjects and methods: This study was based on a clinical cohort and applied flow cytometry to prospectively analyze the ILC subgroups and proportions in OLP and OLL lesions using SPSS software (version 26.0) to attempt cluster analysis to classify diseases at the cellular level based on the phenotype and quantity of ILCs cells, analyze the correlation between the new classification of diseases and clinical risk factors based on the patient's clinical background information and classification results, and evaluate the differences in therapeutic effects among patients in different groups in corresponding clinical cohorts. Results: In the OLP and OLL groups, the ILC compartment consisted mainly of ILC1 (75.02% ± 27.55% and 72.99% ± 25.23%, respectively), ILC2 (1.49% ± 4.12% and 1.72% ± 3.18%, respectively), and ILC3 (16.52% ± 19.47% and 18.77% ± 18.12%, respectively). Using k-means clustering and two-step clustering, patients could be clustered into three groups that did not respond equally to the same treatment. Using k-means clustering, there was a statistically significant difference in REU scores between the ILC1 advantage group and the OLL subgroup before and after treatment ( Conclusions: This study provides a preliminary OLP and OLL classification method based on ILC subgroups that can guide the cytological classification of diseases to a certain extent. Further clinical application values should be verified in subsequent cohort studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.